SAB Biotherapeutics (SABS) Stock Chart & Stock Price History → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free SABS Stock Alerts $4.54 +0.32 (+7.58%) (As of 03/28/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SAB Biotherapeutics Stock Price Performance5 Day Performance-6.97%1 Month Performance+1.79%3 Month Performance+560.36%6 Month Performance+620.63%Year-To-Date Performance+560.36%1 Year Performance+985.09% Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> SABS Stock Chart for Friday, March, 29, 2024 SABS Chart by TradingView SAB Biotherapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization03/28/2024$4.22$4.54+7.58%$4.67$4.224,771 shs$23.74 million03/27/2024$4.17$4.22+1.20%$4.43$4.172,308 shs$22.07 million03/26/2024$4.25$4.17-1.88%$4.43$4.0020,444 shs$21.81 million03/25/2024$4.88$4.25-12.91%$4.95$4.1123,974 shs$22.23 million03/22/2024$4.69$4.88+4.05%$4.88$4.791,351 shs$25.52 million03/21/2024$4.79$4.69-2.09%$4.80$4.695,692 shs$24.53 million Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 03/20/2024$4.80$4.79-0.21%$4.91$4.702,756 shs$25.05 million03/19/2024$5.40$4.80-11.11%$5.52$4.8031,103 shs$25.11 million03/18/2024$5.52$5.40-2.17%$5.89$5.4010,789 shs$28.24 million03/15/2024$6.00$5.52-8.00%$6.30$5.5298,407 shs$28.87 million03/14/2024$5.79$6.00+3.63%$6.09$5.7912,807 shs$31.39 million03/13/2024$5.86$5.79-1.19%$6.15$5.7929,930 shs$30.28 million03/12/2024$5.49$5.86+6.74%$5.88$5.1220,215 shs$30.65 million03/11/2024$5.36$5.49+2.43%$5.50$5.3616,499 shs$28.71 million03/08/2024$5.32$5.36+0.75%$5.36$5.0913,549 shs$28.03 million03/07/2024$5.29$5.32+0.57%$5.34$5.1622,042 shs$27.82 million03/06/2024$4.99$5.29+6.01%$5.30$4.9633,779 shs$27.67 million03/05/2024$4.35$4.99+14.71%$5.00$4.3424,558 shs$26.11 million03/04/2024$4.41$4.35-1.36%$4.43$4.0038,245 shs$22.75 million03/01/2024$4.46$4.41-1.12%$4.58$4.4020,009 shs$23.06 million02/29/2024$4.22$4.46+5.69%$4.96$4.4071,024 shs$23.33 million02/28/2024$4.88$4.22-13.52%$4.80$4.2213,388 shs$22.07 million02/27/2024$4.98$4.88-2.01%$5.04$4.844,698 shs$25.52 million02/26/2024$4.96$4.98+0.40%$5.00$4.904,915 shs$26.05 million02/23/2024$4.98$4.90-1.61%$5.03$4.7110,564 shs$25.63 million02/22/2024$5.17$4.98-3.68%$5.10$4.918,337 shs$26.05 million02/21/2024$5.24$5.17-1.34%$5.25$5.108,222 shs$27.04 million02/20/2024$5.49$5.24-4.55%$5.50$5.1511,542 shs$27.42 million02/19/2024$5.49$5.49$5.60$5.4010,800 shs$28.71 million02/16/2024$5.55$5.43-2.16%$5.60$5.4010,870 shs$28.40 million02/15/2024$5.96$5.55-6.88%$5.90$5.4155,483 shs$29.04 million02/14/2024$5.73$5.96+4.01%$5.96$5.4015,108 shs$31.17 million02/13/2024$5.85$5.73-2.05%$5.97$5.482,238 shs$29.97 million02/12/2024$5.97$5.85-2.01%$6.05$5.7349,301 shs$30.60 million02/09/2024$5.43$5.98+10.09%$5.98$5.4713,875 shs$31.28 million02/08/2024$5.54$5.43-1.95%$5.61$5.431,275 shs$28.41 million02/07/2024$5.53$5.54+0.18%$5.54$5.1913,127 shs$28.97 million02/06/2024$5.56$5.53-0.54%$5.59$5.531,736 shs$28.92 million02/05/2024$5.96$5.56-6.71%$5.98$5.3910,880 shs$29.08 million02/02/2024$5.90$5.96+1.02%$5.96$5.822,742 shs$31.17 million“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… 02/01/2024$6.00$5.90-1.67%$5.90$5.754,952 shs$30.86 million01/31/2024$5.93$6.00+1.18%$6.00$5.8824,860 shs$31.39 million01/30/2024$5.99$5.93-1.00%$5.93$5.831,933 shs$31.01 million01/29/2024$5.98$5.99+0.25%$6.00$4.8033,034 shs$31.33 million01/26/2024$6.00$5.98-0.42%$5.98$5.885,158 shs$31.26 million01/25/2024$6.00$6.00$6.00$5.9011,542 shs$31.38 million01/24/2024$6.08$6.00-1.32%$6.00$5.8812,938 shs$31.38 million01/23/2024$5.81$6.08+4.65%$6.10$5.889,821 shs$31.80 million01/22/2024$6.00$5.81-3.17%$5.92$5.695,696 shs$30.39 million01/19/2024$6.13$6.00-2.12%$6.02$5.923,061 shs$31.38 million01/18/2024$6.15$6.13-0.33%$6.19$5.8178,052 shs$32.06 million01/17/2024$6.03$6.15+2.07%$6.15$6.0129,387 shs$32.16 million01/16/2024$5.98$6.03+0.75%$6.20$5.3021,590 shs$31.52 million01/15/2024$5.98$5.98$6.30$5.8340,000 shs$31.28 million01/12/2024$6.22$5.98-3.86%$6.30$5.8240,001 shs$31.28 million01/11/2024$5.90$6.22+5.42%$6.39$5.6722,888 shs$32.54 million01/10/2024$5.94$5.90-0.67%$5.90$5.743,261 shs$30.86 million01/09/2024$6.12$5.94-2.94%$6.00$5.404,865 shs$31.07 million01/08/2024$5.82$6.12+5.15%$6.12$5.6114,679 shs$32.01 million01/05/2024$0.65$5.82+797.04%$6.24$5.5924,061 shs$33.95 million01/04/2024$0.69$0.65-5.83%$0.70$0.6289,621 shs$33.95 million01/03/2024$0.70$0.69-1.57%$0.70$0.6650,237 shs$36.05 million01/02/2024$0.69$0.70+1.82%$0.70$0.6885,233 shs$36.62 million01/01/2024$0.69$0.69$0.70$0.6939,300 shs$35.97 million12/29/2023$0.69$0.69-0.51%$0.70$0.6939,357 shs$35.97 million12/28/2023$0.69$0.69+0.14%$0.71$0.6876,645 shs$36.15 million Related Companies: ACOR Stock Chart CRIS Stock Chart ZIVO Stock Chart APTO Stock Chart SRZN Stock Chart AIM Stock Chart INKT Stock Chart SNTI Stock Chart PMCB Stock Chart TCON Stock Chart Receive SABS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SABS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.